

*IN THE UNITED STATES PATENT AND TRADEMARK OFFICE*

Applicant: Nobuaki TAKAHASI et al.
Title: *ANTI-CD40 ANTIBODY MUTANTS*
Appl. No.: 10/584,345
International Filing Date: 12/24/2004
371(c) Date: 2/26/07
Examiner: Unassigned
Art Unit: Unassigned
Confirmation Number: 3671

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Atty. Dkt. No. 081356-0262

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

An English language abstract of WO 2005/063981 is submitted herewith. Neither a full English translation nor a corresponding English language counterpart of WO 2005/063981 is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date

15 June 2007

By

Stephen A. Bent

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: June 15, 2007

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/584,345
Filing Date	12/24/2004
First Named Inventor	Nobuaki TAKAHASHI
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	081356-0262

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
	B1	2003/0211100	11/13/2003	BEDIAN et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)				
	B2	WO 2005/063981 A1	7/14/2005	KIRIN BEER KABUSHIKI KAISHA		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	B3	Tong AW et al., "Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro", BLOOD, Vol. 84, Issue 9, pp. 3026-3033, 11/11/1994.	
	B4	M. URASHIMA et al., "CD40 ligand triggered interleukin-6 secretion in multiple myeloma", BLOOD, Vol. 85, Issue 7, pp. 1903-1912, 4/1/1995.	
	B5	Yu-Tzu TAI et al., "CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF- κ B signaling", BLOOD, April 1, 2004, Vol. 101, No. 7, pp. 2762-2769.	
	B6	T. HAYASHI et al., "Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell mediated cytotoxicity against multiple myeloma cells", Br J. Haematol. May 2003, 121(4), pp. 592-596.	

Examiner Signature

/Phillip Gambel/

08/16/2009

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.